A Multiple-Array SPRi Biosensor as a Tool for Detection of Gynecological–Oncological Diseases

Diagnostics based on the determination of biomarkers in body fluids will be more successful when several biomarkers are determined. A multiple-array SPRi biosensor for the simultaneous determination of CA125, HE4, CEA, IL-6 and aromatase has been developed. Five individual biosensors were placed on the same chip. Each of them consisted of a suitable antibody covalently immobilized onto a gold chip surface via a cysteamine linker by means of the NHS/EDC protocol. The biosensor for IL-6 works in the pg mL−1 range, that for CA125 in the µg mL−1 range, and the other three within the ng mL−1 range; these are ranges suitable for the determination of biomarkers in real samples. The results obtained with the multiple-array biosensor are very similar to those obtained with a single biosensor. The applicability of the multiple biosensor was demonstrated using several examples of plasma from patients suffering from ovarian cancer and endometrial cyst. The average precision was 3.4% for the determination of CA125, 3.5% for HE4, 5.0% for CEA and IL-6, and 7.6% for aromatase. The simultaneous determination of several biomarkers may be an excellent tool for the screening of the population for earlier detection of diseases.

[1]  E. Gorodkiewicz,et al.  Biosensors for the Determination of Protein Biomarkers , 2023, Biosensors.

[2]  E. Gorodkiewicz,et al.  Two Biosensors for the Determination of Interleukin-6 in Blood Plasma by Array SPRi , 2022, Biosensors.

[3]  N. López-Andrés,et al.  Diagnostic performance of serum interleukin-6 in pediatric acute appendicitis: a systematic review , 2022, World Journal of Pediatrics.

[4]  M. Plebanski,et al.  Elevated Interleukin-6 Levels in the Circulation and Peritoneal Fluid of Patients with Ovarian Cancer as a Potential Diagnostic Biomarker: A Systematic Review and Meta-Analysis , 2021, Journal of Personalized Medicine.

[5]  Xianghong Zhang,et al.  The diagnostic value of interleukin 6 as a biomarker for gastric cancer , 2021, Medicine.

[6]  Ailing Zhong,et al.  A combined strategy of TK1, HE4 and CA125 shows better diagnostic performance than Risk of Ovarian Malignancy Algorithm (ROMA) in ovarian carcinoma. , 2021, Clinica chimica acta; international journal of clinical chemistry.

[7]  Beata Szymanska,et al.  An SPRi Biosensor for Determination of the Ovarian Cancer Marker HE4 in Human Plasma , 2021, Sensors.

[8]  M. Trovato,et al.  Interleukin-6 signalling as a valuable cornerstone for molecular medicine (Review) , 2021, International journal of molecular medicine.

[9]  F. Vellieux,et al.  Interleukin-6: Molecule in the Intersection of Cancer, Ageing and COVID-19 , 2020, International journal of molecular sciences.

[10]  K. Hermanowicz-Szamatowicz,et al.  An immunosensor for the determination of carcinoembryonic antigen by Surface Plasmon Resonance Imaging. , 2020, Analytical biochemistry.

[11]  M. Quinn,et al.  Pre-operative sera interleukin-6 in the diagnosis of high-grade serous ovarian cancer , 2020, Scientific Reports.

[12]  E. Gorodkiewicz,et al.  Plasma aromatase as a sensitive and selective potential biomarker of bladder cancer and its role in tumorigenesis. , 2019, Oncology letters.

[13]  E. Gorodkiewicz,et al.  A biosensor for determination of the circulating biomarker CA125/MUC16 by Surface Plasmon Resonance Imaging. , 2020, Talanta.

[14]  W. Warchoł,et al.  Human Epididymis Protein 4 (HE4) Reference Limits in Polish Population of Healthy Women, Pregnant Women, and Women with Benign Ovarian Tumors , 2019, Disease markers.

[15]  J. Homola,et al.  Peptide Functionalization of Gold Nanoparticles for the Detection of Carcinoembryonic Antigen in Blood Plasma via SPR-Based Biosensor , 2019, Front. Chem..

[16]  Jinping Li,et al.  Comparison of serum human epididymis protein 4 and CA125 on endometrial cancer detection: A meta-analysis. , 2019, Clinica chimica acta; international journal of clinical chemistry.

[17]  M. Panteghini,et al.  Making new biomarkers a reality: the case of serum human epididymis protein 4 , 2018, Clinical chemistry and laboratory medicine.

[18]  Q. Tong,et al.  Combined detection of IL-6 and IL-8 is beneficial to the diagnosis of early stage esophageal squamous cell cancer: a preliminary study based on the screening of serum markers using protein chips , 2018, OncoTargets and therapy.

[19]  Le Minh Tam,et al.  Standard and optimal cut-off values of serum ca-125, HE4 and ROMA in preoperative prediction of ovarian cancer in Vietnam , 2018, Gynecologic oncology reports.

[20]  Yi Huang,et al.  Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors , 2018, Cancer management and research.

[21]  Yue Zhou,et al.  Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer , 2018, Scientific Reports.

[22]  S. Hammes,et al.  Aromatase deficiency in a male patient - Case report and review of the literature. , 2016, Bone.

[23]  M. Panteghini,et al.  Verification of the harmonization of human epididymis protein 4 assays , 2016, Clinical chemistry and laboratory medicine.

[24]  Han Wu,et al.  Diagnostic and Prognostic Value of Serum Interleukin-6 in Colorectal Cancer , 2016, Medicine.

[25]  Ahsen U. Ahmed,et al.  Dysregulation of Aromatase in Breast, Endometrial, and Ovarian Cancers: An Overview of Therapeutic Strategies. , 2016, Progress in molecular biology and translational science.

[26]  Xiao Zhi,et al.  A Novel Electrochemical Microfluidic Chip Combined with Multiple Biomarkers for Early Diagnosis of Gastric Cancer , 2015, Nanoscale Research Letters.

[27]  Arunas Ramanavicius,et al.  Development of a reusable protein G based SPR immunosensor for direct human growth hormone detection in real samples , 2015 .

[28]  Fangying Wu,et al.  Sensitive detection of carcinoembryonic antigen using surface plasmon resonance biosensor with gold nanoparticles signal amplification. , 2015, Talanta.

[29]  Lucia Manganaro,et al.  HE4 in the differential diagnosis of ovarian masses. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[30]  P. Laudanski,et al.  Surface plasmon resonance imaging biosensors for aromatase based on a potent inhibitor and a specific antibody: Sensor development and application for biological material , 2014 .

[31]  Robert Grützmann,et al.  Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study. , 2013, International journal of surgery.

[32]  A. Ramanavičius,et al.  A surface plasmon resonance immunosensor for human growth hormone based on fragmented antibodies , 2013 .

[33]  C. Punt,et al.  Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  A. Miled,et al.  Conflicting Views on the Molecular Structure of the Cancer Antigen CA125/MUC16 , 2010, Disease Markers.

[35]  Yate-Ching Yuan,et al.  Sequence–function correlation of aromatase and its interaction with reductase , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[36]  L. Frati,et al.  HE4: a new potential early biomarker for the recurrence of ovarian cancer , 2010, Tumor Biology.

[37]  Steven J Skates,et al.  A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. , 2009, Gynecologic oncology.

[38]  I. Gipson,et al.  Focus on Molecules: human mucin MUC16. , 2008, Experimental eye research.

[39]  Shung-Haur Yang,et al.  Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? , 2005, The Journal of surgical research.

[40]  Hyun-Il Cho,et al.  In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses. , 2003, Vaccine.

[41]  H. Ozkan,et al.  Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer. , 2003, Hepato-gastroenterology.

[42]  S. Lambard,et al.  Aromatase expression and role of estrogens in male gonad : a review , 2003, Reproductive biology and endocrinology : RB&E.

[43]  L. Bingle,et al.  The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms , 2002, Oncogene.

[44]  M. de las Heras,et al.  Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis. , 2001, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[45]  M. Duffy,et al.  Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? , 2001, Clinical chemistry.

[46]  N. Takemoto,et al.  Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer. , 1999, Japanese journal of clinical oncology.

[47]  F. Grunert,et al.  Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives , 1991, Journal of clinical laboratory analysis.

[48]  J. Jessup,et al.  The structure, metabolism and function of the carcinoembryonic antigen gene family. , 1990, Biochimica et biophysica acta.